Advertisement

Search Results

Advertisement



Your search for all items matches 33996 pages

Showing 451 - 500


head and neck cancer

Cannabis Use and Risk of Head and Neck Cancer

In a study reported in JAMA Otolaryngology–Head & Neck Surgery, Gallagher et al found that individuals with cannabis-related disorder were at an increased risk of head and neck cancer vs those without cannabis-related disorder. Cannabis-related disorders are defined by the excessive use of...

breast cancer
issues in oncology

Gestational Diabetes and Risk for Breast Cancer

Women who develop gestational diabetes may not have a higher likelihood of being diagnosed with breast cancer, according to recent findings that will be presented by Christensen et al at the upcoming European Association for the Study of Diabetes Annual Meeting 2024 (Abstract 180). Background...

pancreatic cancer
issues in oncology

Metastasis-Directed Radiation Therapy Plus Chemotherapy in Oligometastatic Pancreatic Cancer

Researchers have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy may improve progression-free survival in patients with oligometastatic pancreatic cancer, according to a recent study published by Ludmir et al in the Journal of Clinical Oncology and...

lung cancer

Can Neoadjuvant Atezolizumab Set a New Standard for Unresectable Stage III NSCLC?

Immune checkpoint inhibitors, including atezolizumab, have been evaluated in several phase II trials for neoadjuvant therapy in resectable lung cancer, both with and without chemotherapy, such as the LCMC3 trial and CheckMate 816. Ongoing studies, including the IMpower030 trial, are further...

lung cancer

Visceral Pleural Invasion and Recurrence Risk in Patients Undergoing Surgery for NSCLC

In an analysis from the CALGB 140503 trial reported in JAMA Oncology, Nasser Altorki, MD, and colleagues found that pathologically identified visceral pleural invasion was associated with poorer outcomes in patients undergoing surgery for non–small cell lung cancer (NSCLC). Study Details The trial ...

skin cancer

Merkel Cell Carcinoma: Association of ctDNA With Recurrence Risk

In a study reported in the Journal of Clinical Oncology, Akaike et al found that detection of circulating tumor DNA (ctDNA) was associated with an increased risk of recurrence in patients with Merkel cell carcinoma. Study Details In the study, a tumor-informed ctDNA assay was used in 319 patients...

lung cancer

EGFR- and ALK-Altered NSCLC: TKIs With Stereotactic Radiosurgery for Brain Metastases

In a retrospective study (TURBO-NSCLC) reported in the Journal of Clinical Oncology, Pike et al found that the addition of upfront stereotactic radiosurgery (SRS) to central nervous system (CNS)-penetrant tyrosine kinase inhibitor (TKI) treatment prolonged time to CNS progression vs TKI treatment...

lung cancer

Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III CROWN Trial

In an article in the Journal of Clinical Oncology, corresponding author Benjamin J. Solomon, MBBS, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues provided a long-term analysis of 5-year outcomes from the phase III CROWN trial.1 Median progression-free survival had not been...

lymphoma
skin cancer
immunotherapy

FDA Approves Immunotherapy for Relapsed or Refractory CTCL

On August 8, the U.S. Food and Drug Administration (FDA) approved denileukin diftitox-cxdl (Lymphir), a novel immunotherapy for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy. Denileukin diftitox is...

solid tumors

Cancer of Unknown Primary: Molecularly Guided Therapy After Disease Control on Platinum-Based Chemotherapy

In the phase II CUPISCO trial reported in The Lancet, Krämer et al found that molecularly guided therapy in patients with unfavorable nonsquamous cancer of unknown primary who had disease control on first-line platinum-based therapy resulted in better progression-free survival vs patients who...

hematologic malignancies
issues in oncology

Efficacy of a JAK2/mTOR Inhibitor Combination in Controlling Acute Graft-vs-Host Disease

Adding a Janus kinase 2 (JAK2) inhibitor to standard immunosuppressive drugs may not improve prevention of acute graft-vs-host disease in patients with hematologic malignancies undergoing treatment with allogeneic hematopoietic cell transplantation, according to a recent study published by Pidala...

breast cancer
issues in oncology

Primary Ovarian Insufficiency, Early Menopause May Be Linked to Increased Risk of Breast Cancer

The risk of developing breast cancer may be increased among some women who undergo menopause prior to age 46, according to a recent study published by Allen-Brady et al in The Journal of Clinical Endocrinology & Metabolism. Background Early menopause occurs in women aged 40 to 45 years. Primary ...

legislation

Physician Community Comes Together to Urge Congress to Act on Medicare Payment Reform

ASCO, along with more than 100 medical organizations and societies, sent a letter to members of the U.S. House and Senate leadership urging Congress to prioritize and advance several bills and legislative proposals that would provide greater fiscal stability for physicians and reform key elements...

cost of care
breast cancer
gynecologic cancers
colorectal cancer
lung cancer
prostate cancer

Cancer Screening Estimated to Cost $43 Billion Annually in United States

Cancer screening may cost more than $40 billion annually in the United States, according to a recent study published by Halpern et al in the Annals of Internal Medicine. Study Methods and Results In the recent modeling study, investigators used national health-care survey and cost resources data to ...

lung cancer
immunotherapy

Metastatic NSCLC Survival Rates in the Immunotherapy Era

The survival rates of patients with advanced non–small cell lung cancer (NSCLC) have improved since the introduction of the first immunotherapeutic in this population in the United States in 2015, according to a recent study published by Wang et al in Cancer. NSCLC accounts for up to 90% of all...

cns cancers

FDA Approves IDH1/2 Inhibitor for Certain Patients With Astrocytoma or Oligodendroglioma

The U.S. Food and Drug Administration (FDA) has approved vorasidenib (Voranigo), an isocitrate dehydrogenase-1 (IDH1) and -2 (IDH2) inhibitor, for adult and pediatric patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following...

head and neck cancer

Radiation Alone May Be as Effective as Chemoradiation in Patients With Low-Risk Nasopharyngeal Cancer

Nasopharyngeal carcinoma is a rare and aggressive malignant head and neck cancer that is highly prevalent in the southern and southwestern provinces of China. Although the incidence of the cancer is less than 1 per 100,000 in Europe, the United States, and the Pacific, data from the International...

gastroesophageal cancer

Active Surveillance May Enable Patients With Esophageal Cancer to Delay or Avoid Surgery

Although esophageal cancer in the United States is relatively rare—affecting about 22,400 people each year and making up about 1% of all cancer cases—the disease is common in East and Central Asian countries. Nearly 90% of patients with esophageal cancer in Asia are diagnosed with the squamous cell ...

lung cancer

Selpercatinib in East Asian Patients With RET Fusion–Positive NSCLC: LIBRETTO-431

Lung cancer is the leading cause of cancer-related death worldwide, accounting for the highest mortality rates among both men and women. Most lung cancers—between 80% and 85%—are non–small cell lung cancer (NSCLC), and between 1% and 2% of patients are diagnosed with RET-altered NSCLC. The results...

skin cancer

Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.1...

lung cancer

Should Low-Dose CT Screening Be Recommended for Those at Low Risk for Lung Cancer?

Lung cancer remains the leading cause of cancer-related deaths worldwide. Detecting this disease in its early stages significantly improves survival rates, making low-dose computed tomography (CT) screening an essential component in the fight against lung cancer. Recent studies, particularly from...

issues in oncology
solid tumors

Daily E-Cigarette Use May Be Linked to Higher Combustible Cigarette Cessation

U.S. adults who use e-cigarettes daily and smoke combustible cigarettes may be more likely to quit smoking traditional cigarettes compared with those who smoke but use e-cigarettes less frequently, according to a recent study published by Kasza et al in JAMA Network Open. The findings suggest that...

gynecologic cancers
leukemia
survivorship

Births and Adverse Obstetric Outcomes Among Female Survivors of Adolescent and Young Adult Cancers

In a population-based retrospective cohort study (Teenage and Young Adult Cancer Survivor Study; TYACSS) reported in The Lancet Oncology, Sunguc et al identified risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancers in England and Wales. Study Details The...

lung cancer
genomics/genetics

EGFR-Mutated NSCLC: Tepotinib/Osimertinib in Patients With MET Amplification

In the phase II INSIGHT 2 trial reported in The Lancet Oncology, Yi-Long Wu, MD, and colleagues found that the combination of tepotinib plus osimertinib showed clinically meaningful activity in patients with advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) with MET...

gynecologic cancers

Sacituzumab Govitecan in Advanced Endometrial Cancer

As reported in the Journal of Clinical Oncology by Alessandro D. Santin, MD, and colleagues, findings in the endometrial cancer cohort of the phase II multicohort TROPiCS-03 trial indicated activity of the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy in pretreated patients...

hematologic malignancies
issues in oncology

Investigating Fungal Bloodstream Infections in Bone Marrow Transplant Recipients

Researchers may have uncovered the mechanisms behind fungal bloodstream infections in patients who receive bone marrow transplants, according to a recent study published by Zhai et al in Nature Medicine. Background A phenomenon known as heteroresistance occurs when a tiny fraction of bacteria...

colorectal cancer
prostate cancer
pancreatic cancer
breast cancer
gynecologic cancers
issues in oncology
supportive care

Common Blood Tests May Improve Early Cancer Diagnosis

The results of routine blood tests could be used to speed up cancer diagnoses among patients with abdominal symptoms, according to a recent study published by Rafiq et al in PLOS Medicine. Background Most patients who report symptoms of abdominal pain or bloating to their physicians are referred...

sarcoma

FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma

On August 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have ...

breast cancer
supportive care
issues in oncology

Novel AI Tool May Predict Risk of Chronic Pain in Patients With Breast Cancer

A novel artificial intelligence (AI) model may prove to be effective at predicting which patients with breast cancer are likely to develop chronic pain, according to a recent study published by Park et al in the Journal of Nursing Scholarship. The findings may help physicians to better understand...

gynecologic cancers

FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly With Chemotherapy

On August 1, the U.S. Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adults with primary advanced or recurrent endometrial cancer. Dostarlimab was previously approved in July 2023 with carboplatin...

lymphoma

Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?

Most patients with extranodal marginal zone lymphoma (MZL) are overtreated, according to Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and Institute of Oncology Research in Bellinzona and the Università della Svizzera Italiana in Lugano. “Aggressive therapy is not needed in...

leukemia

Ponatinib and Blinatumomab in Newly Diagnosed Ph-Positive ALL

In an updated analysis of a single-center phase II trial reported in the Journal of Clinical Oncology, Hagop Kantarjian, MD, and colleagues found that the simultaneous combination of ponatinib and blinatumomab continued to be associated with good outcomes in newly diagnosed patients with...

colorectal cancer

Estrogen Plus Progestin and Risk of Colorectal Cancer

As reported in the Journal of Clinical Oncology by Rowan T. Chlebowski, MD, PhD, and colleagues, long-term follow-up of the Women’s Health Initiative trial showed no benefit of treatment with estrogen plus progestin in reducing the risk of colorectal cancer in postmenopausal women. Study Details...

breast cancer
cardio-oncology

Heart-Sparing Radiation Therapy Technique in Left-Sided Breast Cancer: Benefits and Costs

A model-based analysis reported in JACC: CardioOncology by Busschaert et al suggested that the heart-sparing deep inspiration breath-hold vs free-breathing radiation therapy technique is cost-effective—despite increasing treatment time—and may improve the long-term cardiovascular health of patients ...

lymphoma

Glofitamab Combination Therapy Shows Survival Benefit in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A novel treatment regimen with the bispecific antibody glofitamab has demonstrated improvements in survival outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to data presented at the European Hematology Association (EHA) 2024 Congress.1 The phase III ...

colorectal cancer
hepatobiliary cancer
issues in oncology

Liver Transplantation vs Standard Therapies in Patients With Colorectal Cancer Liver Metastasis

Certain patients with colorectal cancer that has metastasized to the liver may experience improved progression-free survival with liver transplantation compared with standard therapies, according to a recent study published by Byrne et al in JAMA Surgery. Background Colorectal cancer often...

issues in oncology

Education Level, Social Media Awareness May Be Linked to Cancer Fatalism

Investigators have found that patients with a lower level of education and social media awareness may hold more fatalistic beliefs about cancer compared with those who are more skilled at finding information through social media, according to a recent study published by Stimpson et al in Cancer...

issues in oncology

Generation X and Millennials Have Higher Risk for Many Cancers Compared to Older Generations

Even though cancer rates continue to fall in older populations, the disease is becoming ever more common among younger age groups. A recent analysis of data from 13 cancer registries in the United States published by Rosenberg et al in JAMA Network Open found that those born between 1965 and 1980...

lung cancer

New Report Shows Vaping and Smoking Together Increases Lung Cancer Risk Fourfold Compared to Smoking Alone

People who use e-cigarettes in conjunction with cigarette smoking are four times more likely to develop lung cancer than people who just smoke cigarettes, according to new study published by Harris et al the Journal of Oncology Research and Therapy. These findings were consistent across gender and...

head and neck cancer

Recurrent/Metastatic HNSCC: Pembrolizumab Plus Carboplatin and Paclitaxel

As reported in the Journal of Clinical Oncology by Marcin Dzienis, MD, and colleagues, the phase IV KEYNOTE-B10 trial of pembrolizumab plus carboplatin and paclitaxel in the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) showed that the regimen produced...

gynecologic cancers
global cancer care

In Remembrance of My Friend, Lyn Denny, MD, PhD: I Will Never Forget Her

I first met Lyn Denny, MD, PhD, in Ghana, in 2004, when she became the Secretary Treasurer of AORTIC and brought the organization back to life. We’ve been friends ever since. I equate Lyn’s unwavering dedication to bringing health equity to women in Africa to Nelson Mandela’s fight for social...

gynecologic cancers
global cancer care

Gynecologic Oncologist Lynette Ann Denny, MD, PhD, Dies at Age 66

The global oncology and public health communities are mourning the death of Lynette Ann Denny, MD, PhD, a world-renowned gynecologic oncologist and a leading researcher in the prevention of cervical cancer in low-resource settings. Dr. Denny died on June 9, 2024, in Cape Town, South Africa, of...

breast cancer

Early-Stage Breast Cancer: MammaPrint Prediction of Extended Letrozole Benefit

In an analysis from the NRG Oncology/NSABP B-42 trial reported in the Journal of Clinical Oncology, Priya Rastogi, MD, and colleagues found that the 70-gene MammaPrint assay findings did not predict the distant recurrence benefit of extended letrozole therapy vs placebo in patients with...

bladder cancer
genomics/genetics

Can Mutations in DNA Damage Repair Genes Predict Cisplatin Response in Muscle-Invasive Urothelial Carcinoma?

The presence of a mutation in any one of three genes known to be involved in DNA damage repair may be associated with complete pathologic response to cisplatin-based neoadjuvant chemotherapy, as measured by pathologic downstaging at the time of cystectomy in patients with muscle-invasive urothelial ...

multiple myeloma

FDA Approves Daratumumab and Hyaluronidase-fihj With VRd for Multiple Myeloma

On July 30, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for...

hepatobiliary cancer
cardio-oncology

Do Nonstatin Cholesterol-Lowering Drugs Influence the Risk of Hepatic Cancer?

Investigators examined whether nonstatin cholesterol-lowering drugs may affect the risk of hepatic cancer, according to a recent study published by Zamani et al in Cancer. Background Hepatic cancer is the sixth most common cancer type across the world and the third leading cause of cancer-related...

breast cancer

Endocrine-Resistant Metastatic Breast Cancer

This is Part 3 of Next-Generation Therapies for Metastatic Hormone Receptor–Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri...

breast cancer

PIK3CA-Mutated Metastatic Breast Cancer

This is Part 2 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...

breast cancer

ESR1-Mutated Metastatic Breast Cancer

This is Part 1 of Next-Generation Therapies for Metastatic HR-Positive Breast Cancer: Where Are We Headed?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.   In this video, Drs. Virginia Kaklamani, William Gradishar, and Komal Jhaveri discuss the...

lung cancer
immunotherapy

Advanced NSCLC: Association of Intratumoral Escherichia With Overall Survival

In a study reported in the Journal of Clinical Oncology, Arielle Elkrief, MD, and colleagues found that detection of intratumoral Escherichia was associated with improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving single-agent immune checkpoint inhibitor ...

Advertisement

Advertisement




Advertisement